Spitalul Clinic Filantropia — Clinical Trial Site

20 Registered trials

12 Currently recruiting

Organisation

Spitalul Clinic Filantropia

Location

Bucharest, Romania

Identifier

ORG-100040845

Address

Bulevardul Mihalache Ion 11-13, 011171, Romania

Departments

040004: Oncology
Department of Medical Oncology
Gynecology
Medical Oncology
Medical Oncology/ Gynecologic Oncology Unit
Neonatologie
Oncologie Medicala
Oncology
Sectia de Oncologie Ginecologica
Sectia Obstetrica
Spitalul clinic Filantropia

Clinical trials at this site (20)

Search interface

A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-022) Recruiting

2023-508015-23-00 Ovarian cancer recurrent 5 2025-04-11
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A randomized, open-label, phase II trial comparing neoadjuvant endocrine therapy in combination with trastuzumab, pertuzumab +/- the PI3K in… Recruiting

2022-501152-28-00 Breast Cancer 4 2022-12-21
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (OPERA-02) Recruiting

2025-522873-12-00 ER+, HER2- Advanced Breast Cancer 5 2026-02-24
A Phase 2 trial to investigate efficacy and safety of vipoglanstat in women with endometriosis Recruiting

2025-522452-16-00 Endometriosis related pain 4 2025-12-05
Study of Izalontamab Brengitecan (BMS-986507) versus Treatment of Physician’s Choice in Patients with Previously Untreated, Locally Advanced… Recruiting

2024-519871-24-00 Breast cancer 10 2025-11-11
A clinical study of sac-TMT in people with breast cancer (MK-2870-032) Recruiting

2024-520190-12-00 Breast Cancer: triple negative breast cancer (TNBC) and 5 2025-11-10
A clinical study of sacituzumab tirumotecan with or without pembrolizumab in people with breast cancer (MK-2870-011) Recruiting

2024-516834-36-00 Locally recurrent unresectable or metastatic TNBC with 5 2025-07-08
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting

2023-504323-25-01 breast cancer 5 2024-03-19
A study to Evaluate Efficacy and Safety of Giredestrant Compared with Fulvestrant (plus a CDK4/6 inhibitor), in Participants with ER+ HER2-N… Recruiting

2022-502980-39-00 Estrogen receptor (ER)-positive, HER2-negative advanced 5 2024-01-25
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable… Ended

2023-504195-14-00 PD-L1-negative metastatic triple-negative breast cancer 5 2022-08-31
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive… Ended

2023-503568-18-00 Early human epidermal growth factor receptor 2 (HER2) p 5 2021-04-13
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
A phase II/III multi-centre, open-label, parallel group study to prove the non-inferiority of safety and efficacy of Metronidazole/Neomycin … Halted

2024-518862-28-00 female patients with bacterial vaginosis (BV), respecti 10 2024-11-19
A multicentre, single arm trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgestrel Vaginal Delivery System) during 1… Ended

2022-502023-21-00 Prevention of pregnancy 5 2023-07-12
A pivotal, multicentre, randomised, open-label, parallel-group trial on contraceptive efficacy, safety and tolerability of LVDS (Levonorgest… Ended

2022-502024-51-00 Prevention of pregnancy 5 2023-07-12
A study to test the safety of MK-1654 and how well MK-1654 works in healthy infants Ended

2022-500350-42-01 Prevention of RSV 10 2022-11-07